Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)

Market Cap	86.83B
Revenue (ttm)	2.71B
Net Income (ttm)	-194.20M
Shares Out	1.27B
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	58.61
Dividend	0.32 (0.47%)
Ex-Dividend Date	Jun 3, 2024

Volume	1,217,223
Open	69.22
Previous Close	69.22
Day's Range	68.41 - 69.40
52-Week Range	40.14 - 88.00
Beta	2.25
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 18, 2024

About Beijing Wantai Biological Pharmacy Enterprise

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vac...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 3,843
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603392

Financial Performance

In 2023, 603392's revenue was 5.51 billion, a decrease of -50.73% compared to the previous year's 11.19 billion. Earnings were 1.25 billion, a decrease of -73.65%.